

# Takaomi Kessoku

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5070549/takaomi-kessoku-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31  
papers

741  
citations

8  
h-index

27  
g-index

44  
ext. papers

1,043  
ext. citations

3.6  
avg, IF

3.28  
L-index

#	Paper	IF	Citations
31	Expert Consensus Document: Diagnosis for Chronic Constipation with Faecal Retention in the Rectum Using Ultrasonography.. <i>Diagnostics</i> , <b>2022</b> , 12,	3.8	1
30	Learning Curve of Endoscopic Retrograde Cholangiopancreatography Using Single-Balloon Enteroscopy.. <i>Digestive Diseases and Sciences</i> , <b>2022</b> , 1	4	0
29	Development of a list of competencies and entrustable professional activities for resident physicians during death pronouncement: a modified Delphi study.. <i>BMC Medical Education</i> , <b>2022</b> , 22, 119	3.3	1
28	Development and Validation of the Death Pronouncement Burden Scale for Oncology Practice.. <i>Palliative Medicine Reports</i> , <b>2022</b> , 3, 39-46	1	1
27	Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. <i>Journal of Gastroenterology</i> , <b>2021</b> , 56, 1022-1032	6.9	6
26	Vitamin B6 efficacy in the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, single-center trial. <i>Journal of Clinical Biochemistry and Nutrition</i> , <b>2021</b> , 68, 181-186	3.1	4
25	Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2021</b> , 36, 2275-2284	4	6
24	Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. <i>Hepatology Communications</i> , <b>2021</b> ,	6	9
23	The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	4
22	Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake. <i>Oncologist</i> , <b>2021</b> , 26, e1862-e1869	5.7	0
21	Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. <i>BMJ Open Diabetes Research and Care</i> , <b>2021</b> , 9,	4.5	14
20	Evaluation of a combination protocol of CT-first triage and active telemedicine methods by a selected team tackling COVID-19: An experimental research study. <i>Journal of Infection and Public Health</i> , <b>2021</b> , 14, 1212-1217	7.4	1
19	A Survey of Palliative Care Ward Nurses' Awareness, Feelings, Behavioral Intentions and Hands-on Experience in Supporting an Environment in Which End-of-life Cancer Patients Nurture Love with Their Partners. <i>Palliative Care Research</i> , <b>2021</b> , 16, 153-162	0.1	
18	Tapentadol Safety and Patient Characteristics Associated with Treatment Discontinuation in Cancer Therapy: A Retrospective Multicentre Study in Japan. <i>Pain and Therapy</i> , <b>2021</b> , 10, 1635-1648	3.6	0
17	Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 555963	5.3	
16	Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study. <i>Trials</i> , <b>2020</b> , 21, 453	2.8	2
15	Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). <i>Contemporary Clinical Trials Communications</i> , <b>2020</b> , 17, 100516	1.8	7

14	Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 996-1007	18.8	7
13	"Guidebook on Doctors' Behaviors for Death Diagnosis Created by Community Healthcare Providers" Changed Residents' Mind for Death Diagnosis. <i>Journal of Palliative Care</i> , <b>2020</b> , 825859720951698	1.8	2
12	Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease. <i>BMJ Open</i> , <b>2020</b> , 10, e037961	3	3
11	Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , <b>2019</b> , 49, 872-880	5.1	10
10	Naldemedine for opioid-induced constipation in patients receiving palliative care: A real-world registry study (Phase-R OIC Study).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 11582-11582	2.2	1
9	Low body mass index and old age are useful in predicting the hemoglobin A1c-lowering effect of switching from sitagliptin to dulaglutide in Japanese patients with type 2 diabetes mellitus: a single-center, open-label, single-arm, pilot study. <i>Diabetology International</i> , <b>2018</b> , 9, 189-195	2.3	2
8	Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. <i>Contemporary Clinical Trials</i> , <b>2018</b> , 69, 40-47	2.3	3
7	Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. <i>BMC Gastroenterology</i> , <b>2017</b> , 17, 96	3	4 <sup>0</sup>
6	Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers. <i>PLoS ONE</i> , <b>2017</b> , 12, e0175626	3.7	24
5	Report of Effect on the Medical Education of the Guidebook about the Behaviors of Physicians on the Death Pronouncement. <i>Palliative Care Research</i> , <b>2017</b> , 12, 906-910	0.1	
4	Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis. <i>Scientific Reports</i> , <b>2016</b> , 6, 22251	4.9	4 <sup>8</sup>
3	Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. <i>Gastroenterology</i> , <b>2016</b> , 150, 626-637.e7	13.3	43 <sup>8</sup>
2	The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. <i>PLoS ONE</i> , <b>2016</b> , 11, e0146337	3.7	105
1	Case reports: chemoradiotherapy for locally advanced neuroendocrine carcinoma of the gallbladder. <i>Clinical Journal of Gastroenterology</i> ,	1.1	0